Search
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawnDarvadstrocel is a suspension of expanded human allogeneic adipose-derived mesenchymal stem cells extracted from the subdermal adipose tissue of healthy donors via liposuction. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.
Cryptomeria japonica bark
go.drugbank.com/drugs/DB16633InvestigationalMixtures: S GVD Phytoncide, S GVD PhytoncideSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalto treat T-cell lymphoma. … The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsDonanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigationalDonanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (, Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimerOrticumab
go.drugbank.com/drugs/DB16653InvestigationalOrticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).
Bentracimab
go.drugbank.com/drugs/DB16659InvestigationalBentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
Categories: Heterocyclic Compounds, 2-RingEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalEndogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … episodes in patients with hemophilia A.
Oxelumab
go.drugbank.com/drugs/DB16663InvestigationalOxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Pimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Torudokimab
go.drugbank.com/drugs/DB16671InvestigationalTorudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).